Evidence map›Paper›PMID 37180581›Full record

ArticlePeerJ2023

Increased death and exhaustion of CD69

Ying Wang, Zhengyi Sun, Xue Du, Qiuyang Yu, Chao Sun, Jing Huang, Liying Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ying WangDepartment of Laboratory Medicine, The First Hospital of Jilin University, Changchun, China.
Zhengyi SunDepartment of Laboratory Medicine, The First Hospital of Jilin University, Changchun, China.
Xue DuDepartment of Laboratory Medicine, The First Hospital of Jilin University, Changchun, China.
Qiuyang YuDepartment of Laboratory Medicine, The First Hospital of Jilin University, Changchun, China.
Chao SunCancer Centre, The First Hospital of Jilin University, Changchun, China.
Jing HuangDepartment of Laboratory Medicine, The First Hospital of Jilin University, Changchun, China.
Liying WangInstitute of Pediatrics, The First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The application of PD-1 monoclonal antibody (mAb) helps to treat non-small cell lung cancer, but acquired resistance has emerged in clinical practice. We tested the hypothesis that acquired resistance of anti-PD-1 immunotherapy is linked to death and exhaustion of activated T and NK cell. Methods: The co-culture system of HCC827 cells and peripheral mononuclear cells (PBMCs) was established to evaluate the effect of PD-1 mAb on the death rate and exhaustion of T and NK cell. The predisposing role of CD69 for death and exhaustion was validated by using PHA-activated PBMCs of CD69 Results: We found that PD-1 mAb increase the death and exhaustion of T cells and NK cells in a dose-dependent way when PBMCs from NSCLC patients whose the percentages of CD69 Conclusions: Our findings imply that increased death and exhaustion of CD69

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, T-LymphocyteCoculture TechniquesHumansKiller Cells, NaturalT-LymphocytesAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, T-LymphocyteAcquired resistanceNatural killer cellsPD-1 monoclonal antibodyT cellsTumor microenvironment

Identifiers

PMID37180581
PMCPMC10174060
OpenAlexW4375866495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.